Company Overview and News

5
126
Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

2018-09-07 seekingalpha - 3
Discussion: On September 4, Recro Pharma (REPH) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the company now plans to submit a revised NDA by the end of this month. Suggestions offered by the FDA now guides the company to include revised labelling language and further information on extractable and leachable items.
DOVA MNKD SYBX TSRO REDIF AST OPK RDHL PBYI ZGNX SNGX DVAX ADRO ALXN BIIB AGLE EIGR HZNP EYEG HSDT CHEK EYEGW SNY BCRX SAGE REPH JNJ UTHR APLS

 
Dynavax Announces Publication of Preclinical Study of TLR9 Agonist in Lung Cancer

2018-09-04 globenewswire
BERKELEY, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced publication of a preclinical study demonstrating that inhalation of a TLR9 agonist can stimulate effective immunity against lung tumors and complement the actions of PD-1 blockade to generate durable, systemic anti-tumor immunity. The paper titled Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T cell Interplay, by Dynavax scientists M.
DVAX

1
Melanoma Combo Immunotherapy Increases Toll for Improved Efficacy

2018-08-28 genengnews - 1
Researchers are constantly on the hunt to improve the immune systems’ response to tumor cells and are beginning to combine immunotherapy drugs for an even greater response to cancer cells. Now, investigators from the Geffen School of Medicine at UCLA and Dynavax Technologies have just published data from a phase 1b study looking at the combination of the PD-1 blocking biologic pembrolizumab and an experimental agonist of Toll-like receptor 9 (TLR9) called SD-101 for treating aggressive melanoma.
DVAX

 
Dynavax Announces Publication of Two Papers in Leading Oncology Journal Highlighting Data From Clinical Studies of Its TLR9 Agonist, SD-101

2018-08-28 globenewswire
BERKELEY, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that two peer-reviewed papers reporting clinical studies of SD-101 have been published by Cancer Discovery, a journal publication from American Association of Cancer Research (AACR). The investigators report clinical activity and broad immune activation in the tumor microenvironment when SD-101 is administered in combination with either low dose radiation in patients with indolent lymphoma or in combination with PD-1 blockade in patients with unresectable or metastatic melanoma.
DVAX

1
Dynavax Technologies: What Lies Ahead

2018-08-11 seekingalpha - 1
2018 looks like it will continue to be an inflection year with 2019 being a payoff year for the company and its shareholders.
DVAX

 
DVAX / Dynavax Technologies Corp. 8-K (Current Report)

2018-08-08 sec.gov
dvax-8k_20180630.htm
DVAX

 
DVAX / Dynavax Technologies Corp. 10-Q (Quarterly Report)

2018-08-08 sec.gov
dvax-10q_20180630.htm UNITED STATES
DVAX

5
Dynavax Remains On Track After Q2

2018-08-07 seekingalpha - 1
Dynavax reported Q2 earnings on Aug. 6, showing significant progress in its commercialization efforts of Heplisav-B, its best-in-class Hepatitis B vaccine.
DVAX GSK GSK

 
Dynavax Technologies Corp (DVAX) CEO Eddie Gray on Q2 2018 Results - Earnings Call Transcript

2018-08-07 seekingalpha
Good day, everyone. Welcome to the Dynavax Technologies Second Quarter two018 Conference. Today's call is being recorded.
DVAX

2
Dynavax Technologies (DVAX) Reports Q2 Loss, Lags Revenue Estimates

2018-08-06 zacks - 1
Dynavax Technologies (DVAX - Free Report) just came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.
DVAX KRNT AMT BRKS GTLS

 
Dynavax to Host Second Quarter 2018 Financial Results Conference Call

2018-07-30 globenewswire
BERKELEY, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will report financial results for the second quarter ended June 30, 2018 after market close on Monday, August 6, 2018, and host a conference call that day to review the results and provide an update on the launch of HEPLISAV-B® [Hepatitis B Vaccine, (Recombinant) Adjuvanted] and its oncology program at 4:30pm ET/1:30pm PT.
DVAX

29
Cramer's lightning round: The best way to add gold to your portfolio

2018-07-16 cnbc
Barrick Gold Corporation: “Look, I always think people should have some gold. I like the Gold, GLD, or I like gold, the bullion. It is really hard to own the stocks. Barrick? Sell, sell, sell.”
CKRGZ ABX CHKVP ZBRA CHKDH CHKVZ CHKDG CHKWZ CHKDJ DVAX CHKDP CHK.WI CHK ABX

39
Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs

2018-06-28 globenewswire
BERKELEY, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced the formation of a six-member Scientific Advisory Board with significant experience in research, development, and commercialization in the fields of oncology and immunology.
DVAX

40
Dynavax Presents Analysis of Data for Participants Aged 60 to 70 with Diabetes from its Phase 3 Trial of HEPLISAV-B®

2018-06-25 globenewswire - 1
In a Post-Hoc Analysis of Elderly Diabetic Patients, HEPLISAV-B was Well-Tolerated and Induced Higher Rates of Seroprotection than Engerix-B
DVAX

DVAX : Dynavax Technologies Stock Analysis and Research Report

2017-10-16 - Asif

Dynavax Technologies is a clinical-stage immunotherapy company focused on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (“TLR”) stimulation. Dynavax current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist that was selected for characteristics optimal for treatment of cancer, including high interferon induction. Directly injecting SD-101 into a tumor site optimizes its effect by ensuring proximity to tumor-specific antigens. In animal models, SD-101 demonstrated significant anti-tumor effects at both the injected site and at distant sites. Dynavax is conducting a clinical program intended to assess potential efficacy of SD-101 in a range of tumors and in combination with a range of treatments, including checkpoint inhibitors and...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to DVAX / Dynavax Technologies Corp. on message board site Silicon Investor.

Dynavax DVAX Dynavax DVAX Dynavax DVAX ADXS - Advaxis, Inc. (Bulls Board) ADXS - Advaxis, Inc. (Bulls Board) ADXS - Advaxis, Inc. (Bulls Board)
CUSIP: 268158201